Latest News and Press Releases

Patent for benefits supporting cardiovascular applications of MenaQ7® Vitamin K2 OSLO, NORWAY and METUCHEN, NJ (June 14th 2016) – NattoPharma ASA has been awarded a patent that allows the company to...

Et patent som understøtter bruk av MenaQ7® vitamin K2 for hjerte-kar tilstander OSLO, NORGE og METUCHEN, NJ USA (14 juni 2016) – NattoPharma ASA har fått godkjent et brukspatent i USA for vitamin K2...

OSLO, NORWAY and METUCHEN, NJ (May 31, 2016) – Journal of Medicinal Food has published a new study that successfully tested and confirmed the role of vitamin K2 as MK-7 (menaquinone-7; MenaQ7®...

Frode Marc Bohan was re-elected as Chairman of the Board of Directors for NattoPharma ASA at the company’s Annual General Meeting, held Friday 20th May, 2016. Frode Marc Bohan is re-elected for a...

Please see attached minutes of meeting from the Ordinary Annual General Meeting in NattoPharma ASA, held on May 20th2016. For more information, please contact: Kjetil Ramsøy CFO,...

Please find attached the 1stQuarter 2016 Earnings Release. Highlights for the quarter, · Record quarter revenue at NOK 12,5 million, 84% growth compared to Q1’15 · Gross Margin at 50,4%, up from...

NattoPharma will release its first quarter 2016 financial results on Friday 20 May 2016 at approximately 08:30 CET. The first quarter 2016 report will be made available at www.nattopharma.com and at...

The Board of Directors of NattoPharma ASA (the "Company") hereby convenes an Annual General Meeting 20 May 2016 at 15:00 hours (CET) at the Company's office in Kirkeveien 59B, 1363 Høvik. Please see...

NattoPharma ASA has today published the Annual Report for 2015. Please see the attached PDF-file. The report is also available to download from the Company's website: www.nattopharma.com. For...

OSLO, NORWAY and METUCHEN, NJ (6 April 2016) – NattoPharma is proud to announce that its complete line of MenaQ7® Vitamin K2 as MK-7 has received verification from the Non-GMO Project, a non-profit...